phospho-CDKN1A/p21 (Thr145)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 5237R
英文名称phospho-CDKN1A/p21 (Thr145)
中文名称磷酸化辫21蛋白抗体
别 名p21 (phospho T145); p-p21 (phospho T145); p21Cip1 (Phospho-Thr145); Activating Fragment 1; CAP20; Cation chloride cotransporter-interacting protein 1; CDK Interacting Protein 1; CDK-interacting protein 1; CDKI; CDKN 1; CDKN1; CDKN1A; CIP1; Cyclin Dependent Kinase Inhibitor 1A; Cyclin-dependent kinase inhibitor 1; Cyclin-dependent kinase inhibitor 1A (P21); Cyclin-dependent kinase inhibitor 1A (p21, Cip1); DNA Synthesis Inhibitor; MDA 6; MDA-6; MDA6; Melanoma Differentiation Associated Protein 6; Melanoma differentiation-associated protein 6; Melanoma differentiation-associated protein; p21; P21 protein; p21CIP1; p21WAF; PIC1; SDI1; SLC12A9; WAF1; Wildtype p53 Activating Fragment 1; Wildtype p53-activated fragment 1; CDN1A_HUMAN.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 **学 信号转导 细胞周期蛋白
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-CDKN1A/p21 (Thr145)抗体交叉反应 Human, Mouse, Rat,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=3ug/Test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量18kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CDKN1A around the phosphorylation site of Thr145 [RQ(p-T)S]:RQ(p-T)S
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-CDKN1A/p21 (Thr145)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. Two families of cyclin dependent kinase inhibitors (CKIs) have been identified. The p21WAF1/Cip1 family inhibits all kinases involved in the G1/S transition. The p16INK4a family inhibits Cdk4 and Cdk6 specifically.
Function:
May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex.
Subunit:
Interacts with HDAC1; the interaction is prevented by competitive binding of C10orf90/FATS to HDAC1 facilitating acetylation and protein stabilization of CDKN1A/p21. Interacts with MKRN1. Interacts with PSMA3. Interacts with PCNA. Component of the ternary complex, cyclin D-CDK4-CDKN1A. Interacts (via its N-terminal domain) with CDK4; the interaction promotes the assembly of the cyclin D-CDK4 complex, its nuclear translocation and promotes the cyclin D-dependent enzyme activity of CDK4. Binding to CDK2 leads to CDK2/cyclin E inactivation at the G1-S phase DNA damage checkpoint, thereby arresting cells at the G1-S transition during DNA repair. Interacts with PIM1.
phospho-CDKN1A/p21 (Thr145)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-CDKN1A/p21 (Thr145)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 LMTK3 丝氨酸/苏氨酸蛋白激酶LMTK3抗体
合格 C20orf201 20号染色体开放阅读框201抗体
合格 PPARGC1A 过氧化物酶体增殖物激活受体γ辅激活子1α抗体
合格 RNF127/LONRF3 环指蛋白127抗体
合格 Vesicular Acetylcholine Transporter 囊泡乙酰胆碱通道抗体
合格 LPCAT1 溶血卵磷脂酰基转移酶1抗体
合格 LPLUNC3 鼻咽癌相关蛋白抗体
合格 LRBA LRBA蛋白抗体
合格 LRP11 低密度脂蛋白受体相关蛋白11抗体
合格 LRRC14 富含亮氨酸重复蛋白14抗体
合格 LRRC17 富含亮氨酸重复蛋白17抗体
合格 LRRC20 富含亮氨酸重复蛋白20抗体
合格 LRRC33 富含亮氨酸重复蛋白33抗体
合格 LRRC34 富含亮氨酸重复蛋白34抗体
合格 LRTM2 富含亮氨酸重复序列跨膜结构域2抗体
合格 LSM11 LSM11蛋白抗体
合格 LSMD1 LSMD1蛋白抗体
合格 LEF-1 **增强因子-1抗体
合格 LTV1/C6orf93 6号染色体开放阅读框93抗体
合格 LUZP2 亮氨酸拉链蛋白2抗体
合格 LW1/HSFX1 热休克转录因子家族X连锁1抗体
合格 LXR beta 肝脏X受体β抗体
合格 LXR alpha + LXR beta 肝脏X受体α+肝脏X受体β抗体
合格 LY6G5C/C6orf20 6号染色体开放阅读框20抗体
合格 合格 ZBTB9/ZNF919 锌指蛋白ZNF919抗体
合格 ZC3H11A ZC3H11A蛋白抗体
合格 ZC3H15 ZC3H15蛋白抗体
合格 ZC3H7B ZC3H7B蛋白抗体
合格 合格 MAP1A 微管相关蛋白1A抗体
合格 ZDHHC2/ZNF372 锌指蛋白372抗体
合格 ZDHHC6 ZDHHC6蛋白抗体
合格 ZDHHC8/ZNF378 锌指蛋白378抗体
合格 alpha MSH 促黑细胞**α抗体
合格 Midkine 中期因子/肝素结合生长因子抗体
合格 ZNF289/ARFGAP2 锌指蛋白289抗体
合格 ZNF24 锌指蛋白24抗体